logo
A company you've never heard of plans to invest at least $1B in the Boise area

A company you've never heard of plans to invest at least $1B in the Boise area

Yahoo08-04-2025

Once a small farming town, Kuna may be making a name for itself as a home for big data centers hoping to cash in on Idaho's low electricity rates and nifty sales-tax exemption.
First, the Treasure Valley city drew the interest of Meta, the owner of Facebook and Instagram, which announced in 2022 that it would build an $800 million center in southeast Kuna. Now the city has greenlit a rezoning request for another data center. But not until dozens of residents and a state legislator weighed in.
The at least $1 billion data center, called Gemstone Technology Park, is slated for 620 acres at 3250 S. Locust Grove Road on agricultural land previously owned by Duane Yamamoto, a former Kuna mayor who died in February. Yamamoto was 90.
The Yamamoto family sold the land, which sits roughly six miles west of the planned Meta campus, to Diode Ventures, a Kansas-based infrastructure-development company.
And who will operate the center? A client 'not yet determined,' a representative for Diode told the Idaho Statesman in an email.
At a public hearing Tuesday, April 1, Diode requested that the nearly one-square mile agricultural site be rezoned as industrial for a 'data processing campus.'
On the campus would be the data center, a water treatment plant, and undeveloped land to act as a buffer to neighboring properties to the north, application materials show.
The city previously approved an application to develop more than 2,000 homes on the site. They were never built. Hethe Clark, a Boise lawyer representing Diode, said the data center would be less of a strain than the houses on local resources, including schools, police, and fire.
'The data center will not connect to city water or sewer,' Clark said at the hearing.
Data centers require enormous capital investment. According to Diode's application, this one would be more than $1 billion — at least 25% more than the Meta center's projected investment. Like all data centers coming to Idaho, Diode's will be exempt from sales tax on construction materials and server equipment. And it will be exempt from local property taxes on any investment exceeding $400 million, as long as that investment is at least $1 billion, thanks to a state tax cap on capital investments.
The company is committing over $40 million in direct contribution to some of those local service-providers.
Application materials show that over 20 years, Diode will contribute $10 million to Kuna Police to support additional staff, $30 million to Kuna Fire to build a new fire station, and $500,000 to the Kuna School District to benefit athletics and technology funds.
The centers also require enormous amounts of electricity. At full build-out, the center would consume 600 to 800 megawatts, another Diode representative confirmed at the hearing.
According to an Idaho Power report, one megawatt powers 650 homes on an average day. That means the amount of energy the center is expected to consume could power somewhere between 390,000 and 520,000 homes — about twice as many households as Ada County has.
The Kuna data center is one of several Diode has planned across the country, which are on the rise nationwide thanks to a 'boom in cloud in AI,' Diode's website says.
Clark said the center would be developed in phases over roughly 10 years.
In over three hours of public testimony, Kuna residents appeared torn over the development. According to the hearing's sign-up sheet provided to the Statesman by the city clerk's office, 17 individuals indicated they supported the center, nine were neutral, and 49 opposed.
Some preferred the prospect of a data center, with its promise of hundreds of construction jobs and roughly 100 permanent jobs once built, over that of hundreds, if not thousands, of new homes. The data center was viewed by some as a way to ease the burden of property taxes for homeowners in the city and to avoid impacts to overcrowded Kuna schools.
Many others wanted to preserve the agricultural history of the land and questioned the long-term benefits of the development, as well as its demand for water and electricity.
Kelly Hardy, one resident who testified, noted that data centers consume from 330,000 gallons to 1.1 million gallons of water per day, according to Data Center Dynamics. Other reports show estimates as high as 5 million gallons of water per day.
'Would we take this deal if it didn't come with the checks that are being written by this company today?' Hardy asked the City Council. 'Meaning, would we accept the risks that are coming long-term?'
City Council members, too, expressed differing viewpoints, ultimately voting 2-2 on the application. Mayor Joe Stear cast the tie-breaking vote.
'This area had a development agreement for 3,000 homes,' Stear said in a statement to the Statesman. 'I believe this is a much better use than building that many homes in an urban-wildland interface.'
State Rep. John Gannon, D-Boise, testified that the center would have statewide implications. Gannon told the Statesman in a phone interview that his three main concerns were the property tax cap, the sales tax exemption, and the strain on electricity resources.
By paying property taxes only on $400 million of the $1 billion, Diode would pay roughly $2.4 million a year, based on an estimated 0.006% property tax Gannon calculated from four taxing districts in the area: the city, the county, the school district, and the highway district. Without that cap, Gannon estimated that Diode would have to pay '$6 million for each billion' invested.
'I think the state of Idaho needs to get a lot more out of this than we're getting,' Gannon said.
And when it comes to the 600 to 800 megawatts of electricity, Gannon pointed out that Idaho Power produces roughly 3,700 megawatts for its entire service territory. Idaho Power says it produces 3,500, with summer usage peaking at 3,800, though it buys other producers' electricity to supplement that.
'The concern is, they're going to have to get their electricity from somewhere, and who's going to pay for it?' Gannon said. 'Whether it's going to be spread among all the ratepayers, or whether it's just going to be the data center's obligation?'
Council Member Matt Biggs also pointed to Idaho Power's service capacity at the hearing. Biggs noted that the data center's expected usage would constitute an approximately 15% increase to Idaho Power's total generation.
'That would be a shock to the system,' he said.
Diode is working to complete 'late-stage agreements' with Idaho Power to provide electricity to the center, Clark said at the hearing.
Gannon pursued fixes to his concerns during the 2025 legislative session, which adjourned Friday. One bill would have limited the sales-tax exemption for data centers to only seven years. Another would have required businesses using significant power to cover the full cost of that electricity, rather than Idaho residents, the Statesman reported. Both bills died in the Senate after passing the House.
Diode is moving forward.
'We appreciate the Kuna City Council's confidence in our ability to be good stewards of the land for sustainable growth in Kuna,' said a Diode statement emailed to the Statesman.
'We also appreciate community feedback and will work with city staff and (the Ada County Highway District) to satisfy our commitments to address concerns around traffic and landscape, as we navigate through next steps in the process.'
Responding to follow-up questions, Douglas Self, vice president of Atlas Strategic Communications, told the Statesman in an email that 'Diode doesn't yet have hard timelines but will have more to share soon as plans progress.'
A Diode representative said at the hearing that construction would start in 2026 at the earliest. 'That's aspirational,' the representative said.
A Meridian company on a Forbes best-employers list is laying off workers
Blue Cross of Idaho cuts jobs as state gives contract to for-profit insurers
Micron expansion could create 15k jobs. Where is everyone going to live? Here's an idea

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy of Allergy and Clinical Immunology Congress
Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy of Allergy and Clinical Immunology Congress

Business Upturn

time36 minutes ago

  • Business Upturn

Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy of Allergy and Clinical Immunology Congress

With up to three years of follow-up, a single dose of lonvo-z led to a 98% mean reduction in monthly HAE attack rate in all 10 patients All 10 patients were attack-free and treatment-free for a median of 23 months through the latest follow-up, demonstrating the potential of lonvo-z to become the first one-time therapy for most HAE patients Lonvo-z was well tolerated and continues to demonstrate a favorable safety profile The global Phase 3 HAELO trial of lonvo-z has concluded screening ahead of schedule with more than half screened from U.S. sites; Intellia to provide an update on enrollment in the future CAMBRIDGE, Mass., June 15, 2025 (GLOBE NEWSWIRE) — Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced three-year follow-up data from the Phase 1 portion of the ongoing Phase 1/2 study in patients with HAE after receiving a single dose of lonvoguran ziclumeran (lonvo-z, also known as NTLA-2002). Results were shared in an oral presentation at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025, held June 13-16 in Glasgow, United Kingdom. 'Today's results underscore the promising potential of Intellia's approach to gene editing therapy – a one-time treatment that was well tolerated and offered a highly differentiated, durable effect for patients suffering from a serious disease,' said Intellia President and Chief Executive Officer John Leonard, M.D. 'Seeing all 10 patients in the Phase 1 portion of this study free from both HAE attacks and chronic therapy at nearly two years of median follow-up is incredibly encouraging. These data fuel our optimism for the outcomes of our ongoing Phase 3 HAELO study, which we expect to report in the first half of 2026, and highlight the strong value we believe it will offer patients, physicians and payers.' 'People living with HAE often report a reduced quality of life because they worry about the likelihood of their next attack, either because they still experience attacks or are reminded of it by their use of chronic therapy,' said Dr. Joshua Jacobs, Medical Director, Allergy and Asthma Clinical Research, Inc. 'Based on the data, it is reasonable to expect lonvo-z could offer patients the potential to be free from both physical HAE attacks and the burden of managing chronic HAE treatment.' In the Phase 1 portion of the study, a one-time dose of 25 mg (N=3), 50 mg (N=4) or 75 mg (N=3) of lonvo-z was administered via intravenous infusion and plasma kallikrein protein levels were measured along with HAE attacks. At the time of the February 12 data cutoff, patients were attack-free and treatment-free for a median of nearly two years. With up to three years of follow-up, a single dose of lonvo-z led to a mean reduction in monthly HAE attack rate of 98% over the study period, compared to pre-treatment baseline. For all 10 patients, deep, dose-dependent and durable reductions in plasma kallikrein protein continued to be observed through the latest assessment. Safety Across all three dose levels, lonvo-z has been well tolerated and continues to demonstrate a favorable safety profile consistent with earlier data presented at EAACI in 2024. The most frequent adverse events during the study period were infusion-related reactions (IRRs). IRRs were mostly Grade 1 and resolved with all patients receiving the full dose. With up to 3 years of follow-up, no treatment-emergent serious adverse events were observed, and no treatment-related adverse events were observed during the period following 28 days after dosing. Clinical Development Plans Intellia's global Phase 3, randomized, double-blind, placebo-controlled HAELO trial is ongoing to assess the safety and efficacy of lonvo-z at the 50 mg dosage. The Company announced today the HAELO trial has successfully completed screening ahead of schedule, with over half of the patients being screened in the United States. The study is no longer recruiting and Intellia will provide an update on enrollment in the future. New and longer-term data from the Phase 2 portion of the ongoing Phase 1/2 study is planned to be presented in the second half of 2025. Intellia expects to submit a biologics license application (BLA) in 2026 to support the Company's plans for a U.S. launch in 2027. For more information on HAELO (NCT06634420), please visit About the Lonvoguran Ziclumeran (lonvo-z, also known as NTLA-2002) Clinical Program Intellia's ongoing Phase 1/2 study is evaluating the safety and efficacy of lonvo-z in adults with Type I or Type II hereditary angioedema (HAE). The Phase 1 portion of the study is an international, open-label study designed to identify the dose level of lonvo-z selected for further evaluation in the Phase 2 portion of the study. Enrollment in both portions of the Phase 1/2 study is complete. Intellia dosed the first patient in the global Phase 3, randomized, double-blind, placebo-controlled HAELO trial in January of 2025. Visit (NCT05120830) for more details. About Lonvo-z Based on Nobel Prize-winning CRISPR/Cas9 technology, lonvo-z has the potential to become the first one-time treatment for hereditary angioedema (HAE). Lonvo-z is an investigational in vivo CRISPR-based gene editing therapy designed to prevent HAE attacks by inactivating the kallikrein B1 ( KLKB1 ) gene, which encodes for prekallikrein, the kallikrein precursor protein. Interim Phase 1/2 clinical data showed dramatic reductions in attack rate, as well as consistent, deep and durable reductions in kallikrein levels. Lonvo-z has received five notable regulatory designations, including Orphan Drug and RMAT Designation by the U.S. Food and Drug Administration (FDA), the Innovation Passport by the U.K. Medicines and Healthcare products Regulatory Agency (MHRA), Priority Medicines (PRIME) Designation by the European Medicines Agency, as well as Orphan Drug Designation (ODD) by the European Commission. About Intellia Therapeutics Intellia Therapeutics, Inc. (NASDAQ:NTLA) is a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies. Since its inception, Intellia has focused on leveraging gene editing technology to develop novel, first-in-class medicines that address important unmet medical needs and advance the treatment paradigm for patients. Intellia's deep scientific, technical and clinical development experience, along with its people, is helping set the standard for a new class of medicine. To harness the full potential of gene editing, Intellia continues to expand the capabilities of its CRISPR-based platform with novel editing and delivery technologies. Learn more at and follow us @intelliatx. Forward-Looking Statements This press release contains 'forward-looking statements' of Intellia Therapeutics, Inc. ('Intellia' or the 'Company') within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, express or implied statements regarding Intellia's beliefs and expectations concerning: the safety, efficacy, success and advancement of its clinical programs for lonvoguran ziclumeran or 'lonvo-z' (also known as NTLA-2002) for hereditary angioedema ('HAE'), including the ability to successfully complete its global Phase 3 HAELO study; its expectation to present additional data regarding lonvo-z, including reporting outcomes of the Phase 3 HAELO study in the first half of 2026 and presenting new and longer-term data from the Phase 2 portion of the ongoing Phase 1/2 study of lonvo-z in the second half of 2025; and its expectation to be able to support a biologics license application for lonvo-z for the treatment of HAE by 2026 for a U.S. launch in 2027. Any forward-looking statements in this press release are based on management's current expectations and beliefs of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: risks related to Intellia's ability to protect and maintain its intellectual property position; risks related to Intellia's relationship with third parties, including its contract manufacturers, licensors and licensees; risks related to the ability of its licensors to protect and maintain their intellectual property position; risks related to Intellia's ability to protect and maintain its intellectual property position; risks related to valid third party intellectual property; risks related to Intellia's relationship with third parties, including its licensors and licensees; risks related to the ability of its licensors to protect and maintain their intellectual property position; uncertainties related to regulatory agencies' evaluation of regulatory filings and other information related to our product candidates, including lonvo-z; uncertainties related to the authorization, initiation and conduct of studies and other development requirements for our product candidates, including uncertainties related to regulatory approvals to conduct clinical trials, including our ability to complete the Phase 3 HAELO study for HAE; the risk that any one or more of Intellia's product candidates, including lonvo-z, will not be successfully developed and commercialized; and the risk that the results of preclinical studies or clinical studies will not be predictive of future results in connection with future studies for the same product candidate or Intellia's other product candidates. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause Intellia's actual results to differ from those contained in the forward-looking statements, see the section entitled 'Risk Factors' in Intellia's most recent annual report of Form 10-K and quarterly report on Form 10-Q, as well as discussions of potential risks, uncertainties, and other important factors in Intellia's other filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and Intellia undertakes no duty to update this information unless required by law. Intellia Contacts: Investors:Brittany ChavesSenior Manager, Investor Relations [email protected]

EGBN Investor News: If You Have Suffered Losses in Eagle Bancorp, Inc. (NASDAQ: EGBN), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
EGBN Investor News: If You Have Suffered Losses in Eagle Bancorp, Inc. (NASDAQ: EGBN), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

Business Upturn

time36 minutes ago

  • Business Upturn

EGBN Investor News: If You Have Suffered Losses in Eagle Bancorp, Inc. (NASDAQ: EGBN), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

NEW YORK, June 15, 2025 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Eagle Bancorp, Inc. (NASDAQ: EGBN) resulting from allegations that Eagle Bancorp may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Eagle Bancorp securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses. WHAT TO DO NEXT: To join the prospective class action, go to or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. WHAT IS THIS ABOUT: On April 23, 2025, after market hours, Eagle Bancorp filed with the SEC a current report on Form 8-K, which included an announcement of Eagle Bancorp's Q1 2025 results. Commenting on these results, an article posted on the next day stated that Eagle Bancorp's Q1 2025 announcement revealed a ' notable miss on both earnings per share (EPS) and revenue compared to forecasts.' On this news, Eagle Bancorp's stock price fell 11.3% on April 24, 2025. WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers. Follow us for updates on LinkedIn: on Twitter: or on Facebook: Attorney Advertising. Prior results do not guarantee a similar outcome. ——————————- Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 40th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 [email protected]

What Investors Should Know As Meta Gets (Back) Into Crypto
What Investors Should Know As Meta Gets (Back) Into Crypto

Forbes

timean hour ago

  • Forbes

What Investors Should Know As Meta Gets (Back) Into Crypto

Meta (formerly Facebook) is getting back into crypto Markets and investment trends tend to move in cycles, and the cryptoasset sector is no exception to this rule of the marketplace. As TradFi institutions continue to deploy blockchain affiliated projects, including the launch of a stablecoin by SocGen running on the Ethereum blockchain, the adoption and acceleration of cryptoassets continues virtually unabated. Even as the sentiment toward crypto improves, prices of bitcoin and other cryptocurrencies increase, and the policy landscape pivots toward a pro-growth outlook there remain significant obstacles to mainstream utilization. For example, the tax treatment of crypto is an inhibitor to retail utilization of crypto as a method of payment, and the lack of insurance available for crypto and crypto-adjacent products can make it difficult for institutions to allocate substantial funds to cryptoassets. Against this landscape, exemplified both the increasing adoption and understanding of cryptoassets and applications with the continued limitations to institutional usage, one company stands apart for several reasons. Meta (formerly Facebook) recently has been questioned by Senators Warren and Blumenthal related to its support for the GENIUS Act, and specifically whether or not the firm would block a prohibition on Big Tech firms from owning stablecoin issuers. The specifics of the questioning by the senators will most assuredly change over time, but the letter that has been made publicly available detail that the senators desire specifics as to what the stablecoin plans for Meta are. Let's take a look at why this letter and these questions are important, not only for Meta, but for the cryptoasset marketplace at large. Meta, then operating as Facebook, already attempted to launch of a native stablecoin in 2019 via the Libra project which was subsequently rebranded as Diem. This previous effort occurred during an entirely different economic and policy landscape, and occurred as the organization was still contending with intense scrutiny following the 2016 U.S. Presidential election. Issues that were raised at the time dealt with the potential of a stablecoin issued by Facebook serving to weaken competition, compromise user privacy, and lead to continued fractionalization of which entity or organization sets policy for U.S. monetary and fiscal policy. While the cryptoasset landscape and policy outlook for crypto projects has definitively shifted to a more permissive stance the very same issues that were raised during 2019 loom large as Meta returns to the stablecoin marketplace. Specifically, the letter from the Senators cited the track record of privacy violations, scams, and fake news that continue to occur on the platform as risks that a native stablecoin could amplify. Even as stablecoins increasingly become more mainstream, and are approaching a market capitalization nearing $300 billion, Meta might find many of the same issues that stymied earlier efforts being dragged back to the surface. Since Meta is one of the few returning players to the stablecoin space this provides an opportunity for crypto native stablecoins such as Circle, which continues to ride high following its IPO in June. As Meta edges closer to launching its own stablecoin, the spotlight on Big Tech's role in digital money is about to get a lot brighter, especially as these same tech firms continue to invest billions in AI initiatives. For crypto-native firms like Circle, that's not a threat - it's an opportunity. Meta's sheer size and complicated history with data privacy all but guarantee it will draw intense regulatory scrutiny. And that scrutiny will set a new bar for how stablecoins are viewed and governed both in the U.S. and abroad. That's where Circle can shine. Unlike tech giants pivoting into payments, Circle was built in crypto — with regulatory engagement and transparency as core pillars. While Meta faces inevitable trust questions and regulatory hurdles, Circle can double down on its position as the safer, more compliant alternative. In the coming months, expect firms like Circle to lean into this advantage, especially as institutional partners and consumers alike grow more cautious about Big Tech controlling their money. Notably, the ongoing partnership between Circle and Coinbase – two of the largest crypto native firms that are publicly traded in the U.S. – can also serve to assuage concerns of policymakers. Regardless of this specific stablecoin project plays out the following reality is becoming increasingly clear, and some would say urgent, for the crypto marketplace. With tens of billions flowing into the sector, TradFi firms deploying blockchain based solutions and native stablecoins, and policymakers actively debating the GENIUS Act, the crypto audit and attestation narrative continues to seem stuck. While the AICPA continues to issue guidance and updates related to digital asset attestation, controls, and valuation, the authoritative standard setters remain behind the proverbial curve. As stablecoins become more important and integrated with payment, treasury, and lending systems the urgency for definitive and standardized auditing best practices will continue to elevate in importance.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store